Björn Frendéus

6PUBLICATIONS
55CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 15, 2026
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors.

|Jul 28, 2026
Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance.

|Jul 17, 2026
Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity.

|Oct 10, 2025
A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.

Javier Cortés, Araceli Priego, Elena Garralda

|Sep 26, 2025
A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for Immunotherapy.

Kirstie L S Cleary, Monika Semmrich, Linda Martensson

|Jan 21, 2022
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.

Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend

Pageof 1

Frequent Collaborators

4 joint publications

Linda Martensson

4 joint publications

Ingrid Teige

3 joint publications

Kirstie L S Cleary

3 joint publications

Monika Semmrich